Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28801537 | 0.98 | CCR1 (0.32) | CCR1CCR5CCR8 | |
| SCHEMBL314773 | 0.70 | ADORA2A (0.32) | — | |
| SCHEMBL1069237 | 0.69 | ALDH1A1 (0.42) | CCR1CCR8 | |
| SCHEMBL6852244 | 0.67 | CCR1 (0.35) | CCR1CCR5CCR8 | |
| SCHEMBL1716797 | 0.67 | CCR1 (0.59) | CCR1CCR5CCR8 | |
| SCHEMBL27712143 | 0.66 | ADORA2A (0.32) | — | |
| SCHEMBL23618574 | 0.65 | ADORA2A (0.32) | — | |
| SCHEMBL2007375 | 0.65 | ADORA2A (0.52) | — | |
| SCHEMBL4385353 | 0.65 | ADORA2A (0.37) | — | |
| SCHEMBL2007373 | 0.65 | ADORA2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104736539-B | Sepiapterin and the autofrettage of tetrahydrochysene lactoyl pterin | 白鸟制药株式会社 | 2017-09-01 | — | — | CN | disclosed |
| CN-105473733-A | Diagnostic in vitro method | UNIV KOELN | 2016-04-06 | — | — | CN | disclosed |
| CN-102264721-B | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INC. (US) | 2015-12-09 | — | — | CN | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| CN-101171014-B | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-02-15 | — | — | CN | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| CN-100418971-C | Heteroaryl-fused pyrimidinyl compounds as anticancer agents | CHIRON CORP (US) | 2008-09-17 | — | — | CN | disclosed |
| CN-101171014-A | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARM LTD (IE) | 2008-04-30 | — | — | CN | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-1886384-A | Quinazolinone compounds as anticancer agents | CHIRON CORP (US) | 2006-12-27 | — | — | CN | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| CN-1809563-A | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORP (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1798749-A | Heteroryl-fused pyrimidinyl compounds as anticancer agents | CHIRON CORP (US) | 2006-07-05 | — | — | CN | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | CCR1 1294/4885CCR5 1522/4885CCR8 249/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | CCR1 4864/4885CCR5 4839/4885CCR8 4748/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | CCR1 4651/4885CCR5 4594/4885CCR8 4392/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | CCR1 1673/4885CCR5 2435/4885CCR8 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.